Exploring the potential of Gonolobus condurango as a histone deacetylase inhibitor in triple-negative breast cancer cell lines: in vitro study
Several classes of HDAC inhibitors have been shown to be potent and specific anticancer agents. In this study, Gonolobus condurango showed no HDAC inhibitory effect in the TNBC cell lines. Identifying new HDAC inhibitors is important, but they must be well characterized before being used as therapeutic agents in humans.
Authors
- Brigitte Schlegelberger (ORCID: https://orcid.org/0000-0001-5256-1270)
- Vera Schäffer
- Britta Skawran (ORCID: https://orcid.org/0000-0002-0787-4478)
- Beate Vajen (ORCID: https://orcid.org/0000-0002-6973-3339)
- Marlies Eilers
Institutions
- Medizinische Hochschule Hannover (DE)
Publication Details
- Journal
- BMC Complementary Medicine and Therapies
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1186/s12906-025-04896-w
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00